Prime Medicine, Inc. (PRME) Cash Flow Statement
Prime Medicine, Inc. (PRME) generated -$156.1M of operating cash flow over the twelve months to 2026-06-30, spent $797000 on capital expenditure and had free cash flow of -$156.8M, according to EquiReason's reading of its SEC filings.
Source: SEC EDGAR filings · figures as of 2026-06-30 · read by EquiReason
PRMEPrime Medicine, Inc.Follow PRME — free
—
Price chart with a free account
- Market cap
- 665.7M
- P/E TTM
- —
- Dividend yield
- —
- 52-week
- —
- Next earnings
- 30 Oct, in 6 days
| Line | FY2024 Dec 24 | FY2025 Dec 25 | TTM Jun 26 | Trend |
|---|---|---|---|---|
| Operating cash flow | -122.9 | -162.6 | -156.1 | |
| Capital expenditure | 7.3 | 4.5 | -0.8 | |
| Free cash flow | -130.2 | -167.1 | -156.8 | |
| Stock-based compensation | 26.1 | 29.3 | — |
USD millions · SEC XBRL
Prime Medicine, Inc. — questions
- What is Prime Medicine, Inc.'s operating cash flow?
- -$156.1M over the twelve months to 2026-06-30.
- How much does Prime Medicine, Inc. spend on capital expenditure?
- $797000 over the twelve months to 2026-06-30.
- What is Prime Medicine, Inc.'s free cash flow?
- -$156.8M over the twelve months to 2026-06-30: operating cash flow minus capital expenditure.
Every figure on this page comes from Prime Medicine, Inc.'s own SEC filings — see them on SEC EDGAR. Price data is licensed and shown only inside the product.
How these figures are read: methodology · EquiReason.